All Family Resources
All Clinician Resources

Update on a Promising New Drug to Treat JM: Vamorolone

Cure JM is making extraordinary progress in juvenile myositis (JM) research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.

Vamorolone is a steroid replacement with all the benefits of steroid treatment without devastating side effects. Vamorolone is currently in a clinical trial in Duchenne Muscular Dystrophy children.

Findings so far indicate improved safety relative to prednisone. Cure JM is working with vamorolone’s sponsor, ReveraGen, to design a clinical trial to test the drug’s safety in JM children. ReveraGen’s VP of Research, Eric Hoffmann, Ph.D., gives us an update on vamorolone and the status of a clinical trial in JM.

Nutrition and Exercise

How to apply the nutrition and exercise recommendations sometimes provided by healthcare providers and make them work for your family in the “real world.”

Austin Krainz’s Story

Austin Krainz, diagnosed with juvenile dermatomyositis at the age of seven, overcame the challenges of a rare disease with the support of his family and pioneering treatment from Dr. Lauren Pachman. After more than a decade of battling the illness, Austin entered remission, fulfilling his childhood dream of professional racing in Porsche’s GT America series.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Join Now
Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.